<table>
<tr><td>Technology/ Title</td><td colspan="3">DBPR376- New Luteinizing Hormone-Releasing Hormone Receptor (LHRHR)-Targeting Small Molecule Mertansine Conjugate for Cancer Treatment</td></tr>
<tr><td rowspan="2">Technology Type</td><td>☐Biotechnology</td><td colspan="2">☐Device/Diagnostics</td></tr>
<tr><td>■Pharmaceutical</td><td colspan="2">☐Others:_____-</td></tr>
<tr><td rowspan="3">Contact Person</td><td colspan="2">Name: Hua-Hsuan Liang</td><td>Title: Acting Section Chief</td></tr>
<tr><td>Telephone(work): 886-37-206166#33206</td><td>Mobile:</td></tr>
<tr><td colspan="2">Email: huahsuan@nhri.edu.tw</td></tr>
<tr><td>Link</td><td colspan="3">N/A</td></tr>
<tr><td>Technology Description</td><td colspan="3">Ligand-targeted drug conjugates offer enormous potentials to enhance the precision and efficacy of anticancer therapies. Current drug conjugates are designed to target disease-associated antigens or receptors for delivery of toxic agents to tumor sites.

We have employed novel and modified LHRH peptide antagonist as a targeting ligand and combined with patented linker-mertansine for selective drug-delivery to the tumor site through selectively binding to LHRHR with high affinity, and showed potent anticancer efficacies in many different cancer models.

COMPETITIVE ADVANTAGES
➤ Our SMDC presents a pharmacokinetically optimizable, cost-effective, single-component, and chemically defined SMDC for effective treatment of LHRHR-expressing cancers.
➤ It demonstrates potent efficacy (remission) against triple negative breast cancer (TNBC) and ovarian cancer.
➤ Tumor-associated LHRHR can serve as biomarkers for selection of patients.</td></tr>
<tr><td>Intellectual Property</td><td colspan="3">N/A</td></tr>
<tr><td>Key Publications</td><td colspan="3">Luteinizing hormone-releasing hormone receptor (LHRHR), not readily detectable in normal visceral organs, were found to be overexpressed in the plasma membrane of several types of cancers ranging from 86% of prostate cancer, 80% of human endometrial and ovarian cancers, 80% of renal cancer, 50% of breast cancers, and 32–50% of pancreatic cancers.</td></tr>
<tr><td>Business Opportunity</td><td colspan="3">This is a first-in-class and novel design of drug delivery system capable of being developing into theranostics with precision medicine application potential.</td></tr>
</table>